



News Release

April 1, 2026

## PreveCeutical Adopts Semi-Annual Financial Reporting

**Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”)** (CSE: PREV, OTCID: PRVCF, FSE: 18H0) announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting (“SAR”).

Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the “CSE”) to voluntarily move from a quarterly to a semi-annual financial reporting framework. PreveCeutical’s fiscal year ends on December 31. Under the SAR pilot program, the Company will be exempt from filing interim financial reports and related management’s discussion & analysis (MD&A) for its first and third quarters:

- **Interim Period:** PreveCeutical will not file an interim report for the first quarter (Q1) ending March 31, 2026 and the third quarter (Q3) ending September 30, 2026; and
- **Ongoing Reporting:** PreveCeutical will continue to file audited annual financial statements (due within 120 days of December 31, 2025) and six-month interim financial reports (due within 60 days of June 30, 2026).

PreveCeutical confirms it meets the pilot program’s eligibility criteria, which includes being a venture issuer with annual revenues of less than \$10 million and maintaining a clean 12-month continuous disclosure record.

This news release is being filed pursuant to Coordinated Blanket Order 51 - 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers.

### About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please

visit our website [www.PreveCeutical.com](http://www.PreveCeutical.com) or follow us on [Twitter](#) and [Facebook](#).

**On behalf of the Board of Directors of PreveCeutical**

Stephen Van Deventer, Chairman and Chief Executive Officer

**For further information, please contact:**

Stephen Van Deventer: +1 604 306 9669

Or Investor Relations [ir@preveceutical.com](mailto:ir@preveceutical.com)

*Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.*